Platelets play a crucial role in hemostasis; activating and aggregating to arrest bleeding following vascular injury. Platelet activation is a complex and dynamic process, involving the co-ordination ...

Rilzabrutinib, a BTK inhibitor, is approved for ITP, showing significant efficacy in improving platelet response and reducing bleeding symptoms. The LUNA 3 study demonstrated rilzabrutinib's ...

Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should spark some buyer’s delight. The drug, which the French pharma giant acquired through a $3.7 billion buyout of ...

The FDA approved oral rilzabrutinib (Wayrilz) for treating persistent or chronic immune thrombocytopenia (ITP), the agency announced on Tuesday. As the first Bruton's tyrosine kinase (BTK) inhibitor ...

Novel treatment targets BTK through multi-immune modulation to help address root causes of ITP Approval based on LUNA 3 phase 3 study that demonstrated rapid and durable platelet response and ...

An expert discusses how rilzabrutinib, a recently FDA-approved Bruton tyrosine kinase (BTK) inhibitor, targets the autoimmune pathophysiology of immune thrombocytopenia (ITP) by modulating B cells, ...

Sanofi’s oral reversible Bruton’s tyrosine kinase (BTK) inhibitor, Wayrilz (rilzabrutinib), has secured approval from the US Food and Drug Administration (FDA) for adult patients with persistent or ...

Diminished platelet autophagy potentially contributes to thrombocytopenia in cirrhotic patients. H 2 S modulates platelet autophagy and functions possibly via the PDGFR-α/PI3K/Akt/mTOR signaling ...

The prominent role of the BCR signaling in promoting B-CLL cell survival has prompted new therapeutic strategies targeted to signalosome elements. In particular, the most advanced BCR-signaling ...

Sanofi’s Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopeniaNovel treatment targets BTK through multi-immune ...